FDA Updates on Compounded GLP'ss: What California Providers Need to Know
As FDA exclusions from 503B bulk lists proceed, California providers must lean on patient-specific 503A with documentation. Here is the latest FDA update and what it means for your practice.
FDA Updates on Compounded GLP-1s: What California Providers Need to Know
The FDA's regulatory posture on compounded GLP-1 medications has evolved significantly over the past 18 months. For California providers — who face both federal FDA rules and California's own strict compounding regulations — staying current on these developments is essential for compliance.
The Timeline: How We Got Here
2022–2024 (Shortage Period): Semaglutide and tirzepatide were on the FDA shortage list. During this period, both 503A pharmacies and 503B outsourcing facilities had broader authority to compound GLP-1 preparations. The shortage designation provided a legal basis for compounding that would otherwise be restricted.
2025 (Shortage List Removal): The FDA removed semaglutide and tirzepatide from the shortage list, citing improved branded supply. This triggered immediate restrictions on 503B bulk compounding of these agents.
2025–2026 (Enforcement Phase): The FDA has increased enforcement activity against compounders producing GLP-1 preparations that are "essentially copies" of branded products. Warning letters have been issued to 503B facilities and 503A pharmacies that were not complying with the post-shortage rules.
What the FDA Has Said
The "Essentially a Copy" Standard
The FDA has been clear: compounding pharmacies cannot produce copies of commercially available drugs. For GLP-1s, this means:
- A compounded semaglutide preparation that is identical to Wegovy or Ozempic is not permissible
- A compounded tirzepatide preparation that is identical to Zepbound or Mounjaro is not permissible
- Preparations with genuine clinical differentiation (different formulation, additives with documented clinical rationale, specific doses not commercially available) may be permissible under 503A
The 503B Bulk List
The FDA maintains a list of bulk drug substances that 503B outsourcing facilities may use to compound medications. Semaglutide and tirzepatide were added to this list during the shortage period. Following the shortage list removal, the FDA has been proceeding with removing these agents from the 503B bulk list.
Current status: The FDA has issued proposed rules and guidance on the removal of semaglutide and tirzepatide from the 503B bulk list. The process involves a comment period and final rule publication. As of mid-2026, the removal process is ongoing.
Practical implication: 503B facilities should not be producing bulk GLP-1 preparations for office stock unless they have a specific exemption or the preparation is genuinely differentiated.
503A Remains Viable
The FDA has been clear that 503A patient-specific compounding remains viable for GLP-1s when:
- The prescription is for a specific, identified patient
- There is a documented clinical rationale for the compounded preparation
- The preparation is not an "essentially a copy" of a commercially available product
What This Means for California Providers
Document Everything
In the current regulatory environment, documentation is your primary defense. For every compounded GLP-1 prescription:
- Clinical evaluation: Document the patient evaluation, including BMI, comorbidities, and treatment history
- Clinical rationale: Document why the patient needs a compounded preparation (cost, access, specific formulation need, intolerance to commercial product)
- Additive rationale: If the formulation includes B12, glycine, or other additives, document the clinical rationale for each additive specific to this patient
- Informed consent: Document that the patient was counseled that the preparation is compounded and not FDA-approved
- Monitoring plan: Document your plan for monitoring the patient's response and any adverse effects
Verify Your Pharmacy
Before ordering from any compounding pharmacy:
- Verify the pharmacy is licensed in California
- Verify the pharmacy is compliant with current FDA guidance on GLP-1 compounding
- Request the pharmacy's current compliance position on GLP-1 compounding
- Review the pharmacy's COA process
Stay Current
California compounding regulations and FDA guidance are evolving. Subscribe to:
- California Board of Pharmacy updates
- FDA compounding guidance updates
- Professional association communications (AACE, OMA, etc.)
MedClinic Partners monitors these developments in real time and proactively advises our clients on compliance implications.
Contact us with compliance questions →
This content is for informational purposes only and does not constitute legal advice. FDA and California regulations are subject to change. Consult with qualified legal counsel regarding your specific obligations.
Explore Topics
Written by
MedClinic Partners Editorial Team
B2B Medical Supply & Compounding Experts
The MedClinic Partners editorial team is composed of licensed medical operators, compounding compliance specialists, and mass-tort attorneys with direct experience running GLP-1 and peptide programs across all 50 states. Every article is reviewed for clinical accuracy, regulatory compliance, and practical applicability before publication.
Editorial standards: All content on medclinicpartners.com is reviewed by licensed medical operators and compounding compliance specialists before publication. Articles are updated when regulatory guidance changes. This content is for licensed healthcare providers only and does not constitute medical advice.
